

N.B. English translation is for convenience purposes only

The Board of Directors' report referred to in Chapter 13, Section 6 of the Swedish Companies Act

The Board of Directors of NeuroVive Pharmaceutical AB (publ), reg. no. 556595-6538, (the "Company") submits the following report as referred to in Chapter 13, Section 6 of the Swedish Companies Act.

After the submission of the annual report for the financial year 2017, which includes the latest adopted balance sheet and profit and loss account, no events of material significance for the Company's financial position have occurred, except from what is stated in the Company's interim report for the period 1 January 2018 to 30 September 2018, **Appendix 1.**

Place: Lund

Date: December 10, 2018

David Laskow-Pooley

David Bejker

Jan Törnell

Denise Goode